Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
a. Class Insulins, Subclass Rapid Acting Agents U-100
- Admelog
- Apidra
- Fiasp
- Humalog
- Insulin Aspart
- Insulin Lispro
- Lyumjev
- Novolog
- Merilog
b. Class Insulins, Subclass Rapid Acting Agents U-200
- Lyumjev Kwikpen U-200
- Humalog Kwikpen U-200
c. Class Metabolic Dysfunction Agents, Subclass Injectable Diabetic Agents
- Bydureon Bcise
- Byetta
- Exenatide
- Mounjaro
- Ozempic
- Semaglutide
- Tirzepatide
- Trulicity
d. Class Metabolic Dysfunction Agents, Subclass Injectable Weight Loss Agents
- Saxenda
- Wegovy
- Zepbound
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9401. Pre-quotation teleconference is on July 30, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference.